Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Nanomedicine. 2020 May 30;28:102225. doi: 10.1016/j.nano.2020.102225

Figure 4.

Figure 4.

In vitro transfection efficiency of Lipofectamine 3000, Liposome (without surface modification), PF-lip, PFTf-lip, R9F2-lip and R9F2Tf-liposomes encapsulating 1 μg chitosan-pGFP complexes in (A) bEnd.3, (B) glial and (C) primary neuronal cells. Data are expressed as mean ± SD (n=4). Statistically significant (p<0.05) differences are shown as (*) with Lipofectamine 3000 and Liposome (without surface modification), and (†) with R9F2-liposomes. D) Fluorescence microscopy images of GFP expression in bEnd.3, glial and primary neuronal cells treated with PF-lip, PFTf-lip, R9F2-lip and R9F2Tf-liposomes encapsulating 1μg chitosan-pGFP complexes. Scale bar, 100 μm.